|Bid||21.50 x 1800|
|Ask||21.54 x 800|
|Day's range||21.24 - 22.59|
|52-week range||17.15 - 50.10|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Richard Rubino, Chief Financial Officer, will present in a fireside discussion at the Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019 at 8:00 a.m. Eastern Time in New York, NY. Mr. Rubino will provide an Aerie overview and provide a business update.
Aerie (AERI) will acquire Spanish ophthalmic pharmaceutical company, Avizorex Pharma, to add a mid-stage dry eye disease candidate to its pipeline.
Aerie (AERI) delivered earnings and revenue surprises of -2.38% and 5.45%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Aerie (AERI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The nature of investing is that you win some, and you lose some. And there's no doubt that Aerie Pharmaceuticals, Inc...
The CHMP recommends Aerie's (AERI) marketing application for Rhokiinsa to reduce elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.
As the US$994m market cap Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) released another year of negative earnings...
Aerie (AERI) delivered earnings and revenue surprises of 8.05% and 8.47%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Aerie (AERI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anyone researching Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) might want to consider the historical volatility of the...
Ocular's (OCUL) phase III study on OTX-TP for the reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma fails to achieve primary endpoint.